## Kazuhisa Nakano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3004316/publications.pdf

Version: 2024-02-01

81 papers	1,627 citations	19 h-index	315739 38 g-index
82	82	82	2330
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren's syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's Syndrome) Tj ETQq1	1 <sup>1</sup> 0.78431	.4 rgBT /Ove
2	Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. Modern Rheumatology, 2022, 32, 41-49.	1.8	7
3	Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: A retrospective, multicenter, descriptive study. Modern Rheumatology, 2022, 32, 32-40.	1.8	15
4	Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry. Rheumatology, 2022, 61, 1831-1840.	1.9	14
5	Neuropsychiatric systemic lupus erythematosus detected using extravascular spillage signal on dynamic magnetic resonance imaging (Ktrans). Rheumatology, 2022, 61, SI102-SI104.	1.9	1
6	Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. Rheumatology, 2022, 61, 4273-4285.	1.9	3
7	Acromegaly: A Rare Cause of Knee Pain. Internal Medicine, 2022, , .	0.7	0
8	Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. Clinical and Experimental Rheumatology, 2022, 40, 86-96.	0.8	5
9	A case of mixed connective tissue disease complicated by pulmonary hypertension and ascites after addition of pulmonary vasodilators. Modern Rheumatology Case Reports, 2022, , .	0.7	1
10	Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. Rheumatology, 2022, 61, 4875-4884.	1.9	5
11	Short-Term Prognostic Factors in Hospitalized Herpes Zoster Patients and Its Associated Cerebro-Cardiovascular Events: A Nationwide Retrospective Cohort in Japan. Frontiers in Medicine, 2022, 9, 843809.	2.6	3
12	IL-17A promotes vascular calcification in an exÂvivo murine aorta culture. Biochemical and Biophysical Research Communications, 2022, 604, 83-87.	2.1	6
13	Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis. Modern Rheumatology, 2022, 32, 1077-1085.	1.8	1
14	Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders. Modern Rheumatology, 2021, 31, 94-100.	1.8	8
15	Lung transplantation resulted in marked improvement of autoimmunity and scleroderma in diffuse cutaneous systemic sclerosis: a case report. Rheumatology, 2021, 60, e129-e131.	1.9	0
16	2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Modern Rheumatology, 2021, 31, 29-33.	1.8	49
17	Similarity of Response to Biologics Between Elderly-onset Rheumatoid Arthritis (EORA) and Non-EORA Elderly Patients: From the FIRST Registry. Journal of Rheumatology, 2021, 48, 1655-1662.	2.0	10
18	Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases. RMD Open, 2021, 7, e001508.	3.8	17

#	Article	IF	CITATIONS
19	Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis. Rheumatology, 2021, 60, 5452-5462.	1.9	7
20	Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Research and Therapy, 2021, 23, 86.	3 <b>.</b> 5	22
21	A case of systemic lupus erythematosus with marked ascites due to idiopathic non-cirrhotic portal hypertension. Modern Rheumatology Case Reports, 2021, 5, 285-291.	0.7	4
22	Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Annals of the Rheumatic Diseases, 2021, 80, 1130-1136.	0.9	33
23	Stimulator of Interferon Genes-associated Vasculopathy with an Onset in Infancy Diagnosed after the Development of Atypical Pulmonary Lesions During Treatment as Juvenile Idiopathic Arthritis. Internal Medicine, 2021, 60, 1109-1114.	0.7	4
24	Serum TNF $\hat{l}\pm$ levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study. Arthritis Research and Therapy, 2021, 23, 154.	3 <b>.</b> 5	6
25	A Japanese Patient with Anti-PM/Scl and Centromere Antibody-Positive Scleroderma-Amyopathic Dermatomyositis Overlap Syndrome Who Developed Renal Crisis. Modern Rheumatology Case Reports, 2021, , .	0.7	1
26	Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
27	Focal Eosinophilic Myositis. Internal Medicine, 2020, 59, 141-141.	0.7	1
28	A case of systemic lupus erythematosus in which Cushing's syndrome caused by adrenal adenoma accidentally occurred during long-term maintenance therapy with corticosteroids. Modern Rheumatology Case Reports, 2020, 4, 34-38.	0.7	1
29	An autopsy case of a patient with systemic sclerosis who developed marked pulmonary hypertension because of pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma. Modern Rheumatology Case Reports, 2020, 4, 56-62.	0.7	1
30	Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. Annals of the Rheumatic Diseases, 2020, 79, 94-102.	0.9	13
31	5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study. Modern Rheumatology, 2020, 30, 799-806.	1.8	5
32	Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. Arthritis Research and Therapy, 2020, 22, 141.	3 <b>.</b> 5	10
33	Systemic lupus erythematosus with repeated protein-losing enteropathy resulting from different pathological conditions: a case report. Modern Rheumatology Case Reports, 2020, 4, 229-232.	0.7	1
34	Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. Arthritis Research and Therapy, 2020, 22, 136.	3 <b>.</b> 5	16
35	A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumour necrosis factor- $\hat{l}_{\pm}$ (TNF- $\hat{l}_{\pm}$ ) inhibitor, adalimumab. Modern Rheumatology Case Reports, 2020, 4, 196-201.	0.7	2
36	A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease. Modern Rheumatology Case Reports, 2020, 4, 278-282.	0.7	2

#	Article	IF	CITATIONS
37	Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. International Journal of Rheumatic Diseases, 2020, 23, 532-539.	1.9	13
38	The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2020, 23, 549-558.	1.9	10
39	Five Cases of IgG4-related Disease with Nasal Mucosa and Sinus Involvement. Internal Medicine, 2020, 59, 1905-1911.	0.7	7
40	Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators. Modern Rheumatology Case Reports, 2020, 4, 253-261.	0.7	1
41	IgG4-type Multiple Myeloma with Diffuse Enlargement of the Thyroid Requiring Differentiation from IgG4-related Disease. Internal Medicine, 2020, 59, 711-714.	0.7	4
42	Mild Encephalitis/Encephalopathy with Reversible Splenial Lesions in SLE. Internal Medicine, 2020, 59, 2439-2440.	0.7	2
43	An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis. Internal Medicine, 2019, 58, 1023-1027.	0.7	4
44	Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcetâ $\in$ <sup>TM</sup> s disease. Arthritis Research and Therapy, 2019, 21, 151.	3.5	13
45	Successful treatment of acrodermatitis continua of Hallopeau with apremilast. Journal of Dermatology, 2019, 46, e370-e371.	1.2	7
46	IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2. Bone, 2019, 124, 53-61.	2.9	65
47	SAT0026â€IMPACT OF TOCILIZUMAB ON IMMUNE PHENOTYPES IN PATIENTS WITH LARGE VESSEL VASCULITIS 2019, , .	٠,	O
48	FRIO177â€THE ADDITIVE EFFECTS OF HYDROXYCHLOROQUINE TO MAINTENANCE THERAPY WITH STANDARD (CARE IN PATIENTS WITH SYSTEMIC LUPUS: ERYTHEMATOSUS. , 2019, , .	OF	0
49	FRIO246â€CELLULAR/FIBROCELLULAR CRESCENT IS A 52-WEEK AND LONG-TERM POOR PROGNOSTIC FACTOR ACTIVE LUPUS NEPHRITIS. , 2019, , .	OF	O
50	Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor $1\hat{1}^3$ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy. Internal Medicine, 2019, 58, 427-431.	0.7	3
51	Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus. Clinical Immunology, 2019, 200, 1-9.	3.2	11
52	The two cases of acute acalculous cholecystitis associated with systemic lupus erythematosus (SLE) presented different clinical aspects. Modern Rheumatology Case Reports, 2019, 3, 114-118.	0.7	2
53	Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2019, 22, 434-442.	1.9	17
54	Fatal Chronic Active Epstein-Barr Virus Infection in a Rheumatoid Arthritis Patient Treated with Abatacept. Internal Medicine, 2019, 58, 585-591.	0.7	6

#	Article	IF	Citations
55	Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology, 2019, 58, 336-344.	1.9	92
56	Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching. Clinical Immunology, 2018, 191, 67-74.	3.2	12
57	Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. Rheumatology, 2018, 57, 164-174.	1.9	70
58	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). Modern Rheumatology, 2018, 28, 642-648.	1.8	16
59	Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis. Frontiers in Immunology, 2018, 9, 2901.	4.8	58
60	Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. Arthritis Research and Therapy, 2018, 20, 240.	3.5	39
61	Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 1957.	4.8	66
62	lgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion. Internal Medicine, 2018, 57, 2251-2257.	0.7	23
63	Successful Management of Pregnancy in a Patient with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension. Internal Medicine, 2018, 57, 1655-1659.	0.7	4
64	Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. Frontiers in Immunology, 2018, 9, 1510.	4.8	89
65	Successful treatment with etanercept in a case of seronegative rheumatoid arthritis with corticosteroid/methotrexate-resistant pemphigus erythematosus. Modern Rheumatology Case Reports, 2018, 2, 137-142.	0.7	0
66	The occurrence of hypertrophic pachymeningitis with infiltration of IgG4-positive plasma cells and with different aetiology: report of three cases. Modern Rheumatology Case Reports, 2017, 1, 108-112.	0.7	1
67	Induction of Regulatory T Cells and Its Regulation with Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-4 by Human Mesenchymal Stem Cells. Journal of Immunology, 2017, 199, 1616-1625.	0.8	53
68	A case of rheumatoid arthritis treated with infliximab who developed disseminated Penicillium marneffei infection after visit to Thailand. Modern Rheumatology Case Reports, 2017, 1, 43-48.	0.7	4
69	Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Annals of the Rheumatic Diseases, 2016, 75, 1321-1327.	0.9	42
70	Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study. Clinical and Experimental Rheumatology, 2016, 34, 834-841.	0.8	4
71	Histamine inhibits differentiation of skin fibroblasts into myofibroblasts. Biochemical and Biophysical Research Communications, 2015, 463, 434-439.	2.1	16
72	Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Annals of the Rheumatic Diseases, 2015, 74, 389-395.	0.9	149

#	Article	IF	CITATIONS
73	Therapeutic effect of D1-like dopamine receptor antagonist on collagen-induced arthritis of mice. Modern Rheumatology, 2011, 21, 260-266.	1.8	37
74	Dopamine Induces IL-6–Dependent IL-17 Production via D1-Like Receptor on CD4 Naive T Cells and D1-Like Receptor Antagonist SCH-23390 Inhibits Cartilage Destruction in a Human Rheumatoid Arthritis/SCID Mouse Chimera Model. Journal of Immunology, 2011, 186, 3745-3752.	0.8	115
75	Dopamine released by dendritic cells polarizes Th2 differentiation. International Immunology, 2009, 21, 645-654.	4.0	113
76	Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: Preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochemical and Biophysical Research Communications, 2008, 373, 286-291.	2.1	131
77	Engagement of CD44 up-regulates Fas Ligand expression on T cells leading to activation-induced cell death. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 45-54.	4.9	27
78	Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. Modern Rheumatology, 2005, 15, 28-32.	1.8	15
79	Efficacy of mizoribine treatment in patients with Sj�gren?s syndrome: an open pilot trial. Modern Rheumatology, 2003, 13, 339-345.	1.8	2
80	Multiple hepatic infarction after transcatheter arterial infusion with SMANCS. Journal of Gastroenterology, 2001, 36, 415-421.	5.1	6
81	Intercellular adhesion molecule-1 (ICAM-1) mediated gene delivery to rheumatoid synovial cells using the Fab fragments of anti-ICAM-1 monoclonal antibody. Japanese Journal of Clinical Immunology, 2000, 23, 533-537.	0.0	1